Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAME: Qulipta (AbbVie)
- INDICATIONS: Treatment of episodic migraine in adults.
- CLASS: Calcitonin gene-related peptide (CGRP) receptor antagonist
- HALF-LIFE: approximately 11 hours
- FDA APPROVAL DATE: 09/28/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Cimetidine, Ciprofloxacin, Cyclosporine, CYP3A4 inducers, CYP3A4 inhibitors, Esomeprazole, Fluconazole, Grapefruit Juice, Itraconazole, Quinidine, Rifampin - PREGNANCY: No adequate data on the developmental risk associated with the use of atogepant in pregnant women.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 02/18/2024
